NASDAQ:ARTL Artelo Biosciences (ARTL) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free ARTL Stock Alerts $1.34 -0.05 (-3.60%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$1.29▼$1.3950-Day Range$1.28▼$1.5852-Week Range$1.15▼$2.98Volume31,158 shsAverage Volume14,954 shsMarket Capitalization$4.33 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Artelo Biosciences alerts: Email Address Artelo Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside273.1% Upside$5.00 Price TargetShort InterestHealthy0.15% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.07) to ($1.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.06 out of 5 stars 3.5 Analyst's Opinion Consensus RatingArtelo Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageArtelo Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Artelo Biosciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.15% of the float of Artelo Biosciences has been sold short.Short Interest Ratio / Days to CoverArtelo Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Artelo Biosciences has recently decreased by 19.67%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArtelo Biosciences does not currently pay a dividend.Dividend GrowthArtelo Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARTL. Previous Next 2.7 News and Social Media Coverage News SentimentArtelo Biosciences has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Artelo Biosciences this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for ARTL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Artelo Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.90% of the stock of Artelo Biosciences is held by insiders.Percentage Held by InstitutionsOnly 0.87% of the stock of Artelo Biosciences is held by institutions.Read more about Artelo Biosciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Artelo Biosciences are expected to grow in the coming year, from ($2.07) to ($1.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artelo Biosciences is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artelo Biosciences is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtelo Biosciences has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable ProsperityCharles Payne Demystifies OptionsWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. About Artelo Biosciences Stock (NASDAQ:ARTL)Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Read More ARTL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARTL Stock News HeadlinesMay 10, 2024 | globenewswire.comArtelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14thMay 3, 2024 | americanbankingnews.comComparing Artelo Biosciences (NASDAQ:ARTL) and Genus (OTCMKTS:GENSF)May 10, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”April 23, 2024 | globenewswire.comArtelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer TherapyApril 22, 2024 | globenewswire.comArtelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern TimeMarch 25, 2024 | benzinga.comRecap: Artelo Biosciences Q4 EarningsMarch 25, 2024 | msn.comArtelo Biosciences GAAP EPS of -$3.14 misses by $0.58March 25, 2024 | globenewswire.comArtelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business UpdateMay 10, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”March 12, 2024 | globenewswire.comArtelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation ChallengeFebruary 15, 2024 | finanznachrichten.deArtelo Biosciences, Inc.: Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20thJanuary 8, 2024 | finance.yahoo.comArtelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12December 5, 2023 | finance.yahoo.comArtelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in GermanyNovember 16, 2023 | markets.businessinsider.comPromising Developments in Artelo Biosciences’ Cancer Therapies Drive Buy Rating RecommendationNovember 13, 2023 | msn.comArtelo Biosciences GAAP EPS of -$0.83 misses by $0.18November 13, 2023 | finance.yahoo.comArtelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 7, 2023 | morningstar.comArtelo Biosciences Inc ARTLNovember 2, 2023 | finance.yahoo.comArtelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023September 5, 2023 | finance.yahoo.comArtelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13thAugust 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR), Artelo Biosciences (ARTL) and Unity Biotechnology (UBX)June 28, 2023 | markets.businessinsider.comArtelo Biosciences (ARTL) Receives a Buy from Ladenburg Thalmann & Co.June 27, 2023 | msn.comArtelo Unvails New Data On ART26.12 Demonstrating Positive Effects In Multiple Models Of Neuropathic PainJune 27, 2023 | finance.yahoo.comArtelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society SymposiumMay 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Artelo Biosciences (ARTL), Iterum Therapeutics (ITRM) and TScan Therapeutics (TCRX)May 11, 2023 | msn.comArtelo Biosciences: Q1 Earnings InsightsMay 11, 2023 | finance.yahoo.comArtelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business UpdateApril 25, 2023 | finance.yahoo.comArtelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossSee More Headlines Receive ARTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARTL CUSIPN/A CIK1621221 Webwww.artelobio.com Phone(858) 925-7049FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+262.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,290,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.68% Return on Assets-58.15% Debt Debt-to-Equity RatioN/A Current Ratio8.51 Quick Ratio8.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.12 per share Price / Book0.33Miscellaneous Outstanding Shares3,230,000Free Float3,005,000Market Cap$4.46 million OptionableNot Optionable Beta1.44 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Gregory D. Gorgas M.B.A. (Age 61)President, CEO, CFO, Treasurer, Secretary & Director Comp: $742.45kDr. Andrew Yates Ph.D.Senior VP & Chief Scientific OfficerDr. Steven D. Reich (Age 78)Chief Medical Officer Mr. Jason H. Baybutt (Age 52)Senior Vice President of Finance Key CompetitorsEnsysce BiosciencesNASDAQ:ENSCLongeveronNASDAQ:LGVNSoligenixNASDAQ:SNGXExicureNASDAQ:XCURTharimmuneNASDAQ:THARView All Competitors ARTL Stock Analysis - Frequently Asked Questions Should I buy or sell Artelo Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Artelo Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARTL shares. View ARTL analyst ratings or view top-rated stocks. What is Artelo Biosciences' stock price target for 2024? 1 equities research analysts have issued 12 month price targets for Artelo Biosciences' shares. Their ARTL share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 273.1% from the stock's current price. View analysts price targets for ARTL or view top-rated stocks among Wall Street analysts. How have ARTL shares performed in 2024? Artelo Biosciences' stock was trading at $1.40 at the beginning of the year. Since then, ARTL stock has decreased by 4.3% and is now trading at $1.34. View the best growth stocks for 2024 here. Are investors shorting Artelo Biosciences? Artelo Biosciences saw a decline in short interest in April. As of April 30th, there was short interest totaling 4,900 shares, a decline of 19.7% from the April 15th total of 6,100 shares. Based on an average trading volume of 14,400 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the shares of the company are short sold. View Artelo Biosciences' Short Interest. How were Artelo Biosciences' earnings last quarter? Artelo Biosciences, Inc. (NASDAQ:ARTL) issued its quarterly earnings data on Monday, March, 25th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.70. When did Artelo Biosciences' stock split? Artelo Biosciences shares reverse split on Wednesday, August 10th 2022. The 1-15 reverse split was announced on Wednesday, August 10th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Artelo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Artelo Biosciences investors own include NVIDIA (NVDA), VBI Vaccines (VBIV), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Flexion Therapeutics (FLXN), OPKO Health (OPK), Overstock.com (OSTK), Allena Pharmaceuticals (ALNA) and Advanced Micro Devices (AMD). How do I buy shares of Artelo Biosciences? Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARTL) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlaceGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
